+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Humira Market Size, Share & Trends Analysis Report by Product (Branded, Biosimilar), Application (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 6098186
REQUEST CUSTOMIZATION
Description Jump to:
The Humira Market was valued at USD 10.34 billion in 2024, and is projected to reach USD 4.11 billion by 2030, rising at a CAGR of -11.29%. Despite this decline, the market continues to experience sustained demand, driven by the rising global prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Humira has long been a cornerstone of treatment for these conditions, and demand for effective biologic therapies remains strong. However, as the market shifts, the entry of biosimilars and evolving regulatory frameworks are reshaping its dynamics.

The decline in Humira’s market share is largely attributed to the growing availability of biosimilars. With the expiration of key patents, biosimilars, driven by regulatory support and cost-containment strategies, are becoming increasingly accessible, particularly in emerging markets. As a result, there is a shift towards more affordable alternatives, increasing the adoption of biosimilars and expanding patient access. Although Humira’s proven efficacy continues to make it a top choice for managing autoimmune diseases, the increasing presence of biosimilars leads to a competitive pricing environment and reduces its overall market dominance.

Despite the market's decline, significant growth opportunities remain, especially in developing regions where healthcare infrastructure is improving and awareness of autoimmune conditions is rising. The expanding indications for Humira and new formulations, such as citrate-free versions and high-concentration injectables, drive continued demand for the drug, particularly in regions with a strong healthcare framework and reimbursement support.

Pharmaceutical companies, including AbbVie and leading biosimilar manufacturers like Amgen, Sandoz, and Teva, are navigating the evolving landscape through strategic partnerships, product differentiation, and lifecycle management. AbbVie has retained significant market share through brand loyalty, extensive clinical data, and physician trust, despite the emergence of biosimilars in 2024.

Recent developments, such as the launch of interchangeable biosimilars like Simlandi and initiatives like Evernorth’s zero out-of-pocket cost program, highlight the growing push for affordable access. As biosimilars rapidly gain approval and expand market presence, the competitive landscape of the Humira industry is becoming increasingly dynamic. The market is expected to continue evolving, with key players focusing on expanding indications, enhancing delivery systems, and penetrating underserved regions to capitalize on the shifting dynamics of autoimmune disease treatment.

Humira Market Report Highlights

  • Based on product, Branded Humira dominated the market, accounting for 87.0% of the share in 2024. This dominance is attributed to its proven clinical efficacy, wide-ranging regulatory approvals across multiple autoimmune conditions, and long-standing physician and patient trust in the brand.
  • Based on application, rheumatoid arthritis dominated the market and accounted for a share of 20.5% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
  • Based on distribution channel, hospital Pharmacies led the market and accounted for a share of 41.0% in 2024, driven by the growing demand for biologic therapies used in managing autoimmune conditions. Humira is a preferred treatment option prescribed and dispensed through hospital settings for patients requiring specialized care.
  • Key players in the market include AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Samsung Bioepis, and Sandoz. Competition is intensifying with the growing presence of biosimilar manufacturers, especially following the expiration of Humira’s key patents, which has opened the market to a broader range of adalimumab-based therapies.
  • In June 2024, Coherus BioSciences revealed it had completed the sale of its Humira biosimilar, YUSIMRY, to Hong Kong King-Friend Industrial Co. Ltd. for USD 40 million in cash, with the transaction closing on June 26, 2024. YUSIMRY will continue to be commercialized in the U.S. by Meitheal Pharmaceuticals, a subsidiary of HKF. Coherus noted that the divestiture aligns with its strategic focus on advancing its oncology portfolio.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Humira Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Humira Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Branded
4.4.1. Branded Market, 2018-2030 (USD Million)
4.5. Biosimilar
4.5.1. Biosimilar Market, 2018-2030 (USD Million)
Chapter 5. Humira Market: Application Business Analysis
5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Rheumatoid Arthritis
5.4.1. Rheumatoid Arthritis Market, 2018-2030 (USD Million)
5.5. Psoriatic Arthritis
5.5.1. Psoriatic Arthritis Market, 2018-2030 (USD Million)
5.6. Crohn’s Disease
5.6.1. Crohn’s Disease Market, 2018-2030 (USD Million)
5.7. Ulcerative Colitis
5.7.1. Ulcerative Colitis Market, 2018-2030 (USD Million)
5.8. Ankylosing Spondylitis
5.8.1. Ankylosing Spondylitis Market, 2018-2030 (USD Million)
5.9. Others
5.9.1. Others Market, 2018-2030 (USD Million)
Chapter 6. Humira Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2018-2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2018-2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies Market, 2018-2030 (USD Million)
Chapter 7. Humira Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
7.4. North America
7.4.1. North America Humira Market Estimates And Forecasts, By Country, 2018-2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Framework
7.4.2.5. U.S. Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Framework
7.4.3.5. U.S. Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Framework
7.4.4.5. Mexico Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5. Europe
7.5.1. Europe Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Framework
7.5.2.5. Uk Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Framework
7.5.3.5. Germany Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Framework
7.5.4.5. France Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Regulatory Framework
7.5.5.4. Reimbursement Framework
7.5.5.5. Italy Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Target Disease Prevalence
7.5.6.3. Regulatory Framework
7.5.6.4. Reimbursement Framework
7.5.6.5. Spain Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Target Disease Prevalence
7.5.7.3. Regulatory Framework
7.5.7.4. Reimbursement Framework
7.5.7.5. Denmark Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Target Disease Prevalence
7.5.8.3. Regulatory Framework
7.5.8.4. Reimbursement Framework
7.5.8.5. Sweden Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Target Disease Prevalence
7.5.9.3. Regulatory Framework
7.5.9.4. Reimbursement Framework
7.5.9.5. Norway Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Framework
7.6.2.5. Japan Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Framework
7.6.3.5. China Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Framework
7.6.4.5. India Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Framework
7.6.5.5. Australia Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Regulatory Framework
7.6.6.4. Reimbursement Framework
7.6.6.5. South Korea Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Target Disease Prevalence
7.6.7.3. Regulatory Framework
7.6.7.4. Reimbursement Framework
7.6.7.5. Thailand Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Target Disease Prevalence
7.7.2.3. Regulatory Framework
7.7.2.4. Reimbursement Framework
7.7.2.5. Japan Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Target Disease Prevalence
7.7.3.3. Regulatory Framework
7.7.3.4. Reimbursement Framework
7.7.3.5. China Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Humira Market Estimates and Forecasts, 2017-2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Target Disease Prevalence
7.8.2.3. Regulatory Framework
7.8.2.4. Reimbursement Framework
7.8.2.5. South Africa Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Target Disease Prevalence
7.8.3.3. Regulatory Framework
7.8.3.4. Reimbursement Framework
7.8.3.5. Saudi Arabia Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Target Disease Prevalence
7.8.4.3. Regulatory Framework
7.8.4.4. Reimbursement Framework
7.8.4.5. UAE Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Target Disease Prevalence
7.8.5.3. Regulatory Framework
7.8.5.4. Reimbursement Framework
7.8.5.5. Kuwait Humira Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. AbbVie
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Alvotech
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Amgen Inc.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Boehringer Ingelheim Pharmaceuticals Inc.
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Celltrion Inc.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Coherus Biosciences, Inc
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Fresenius Kabi AG
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Fujiflim Kyowa Kiran Biologics Co., Ltd.
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Pfizer Inc.
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Samsung Bioepis
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. Sandoz Inc.
8.5.11.1. Overview
8.5.11.2. Financial Performance
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global Humira market, by region, 2018-2030 (USD Million)
Table 4. Global Humira market, by product, 2018-2030 (USD Million)
Table 5. Global Humira market, by application, 2018-2030 (USD Million)
Table 6. Global Humira market, by distribution channel, 2018-2030 (USD Million)
Table 7. North America Humira market, by country, 2018-2030 (USD Million)
Table 8. North America Humira market, by product, 2018-2030 (USD Million)
Table 9. North America Humira market, by application, 2018-2030 (USD Million)
Table 10. North America Humira market, by distribution channel, 2018-2030 (USD Million)
Table 11. U.S. Humira market, by product, 2018-2030 (USD Million)
Table 12. U.S. Humira market, by application, 2018-2030 (USD Million)
Table 13. U.S. Humira market, by distribution channel, 2018-2030 (USD Million)
Table 14. Canada Humira market, by product, 2018-2030 (USD Million)
Table 15. Canada Humira market, by application, 2018-2030 (USD Million)
Table 16. Canada Humira market, by distribution channel, 2018-2030 (USD Million)
Table 17. Mexico Humira market, by product, 2018-2030 (USD Million)
Table 18. Mexico Humira market, by application, 2018-2030 (USD Million)
Table 19. Mexico Humira market, by distribution channel, 2018-2030 (USD Million)
Table 20. Europe Humira market, by country, 2018-2030 (USD Million)
Table 21. Europe Humira market, by product, 2018-2030 (USD Million)
Table 22. Europe Humira market, by application, 2018-2030 (USD Million)
Table 23. Europe Humira market, by distribution channel, 2018-2030 (USD Million)
Table 24. UK Humira market, by product, 2018-2030 (USD Million)
Table 25. UK Humira market, by application, 2018-2030 (USD Million)
Table 26. UK Humira market, by distribution channel, 2018-2030 (USD Million)
Table 27. Germany Humira market, by product, 2018-2030 (USD Million)
Table 28. Germany Humira market, by application, 2018-2030 (USD Million)
Table 29. Germany Humira market, by distribution channel, 2018-2030 (USD Million)
Table 30. France Humira market, by product, 2018-2030 (USD Million)
Table 31. France Humira market, by application, 2018-2030 (USD Million)
Table 32. France Humira market, by distribution channel, 2018-2030 (USD Million)
Table 33. Italy Humira market, by product, 2018-2030 (USD Million)
Table 34. Italy Humira market, by application, 2018-2030 (USD Million)
Table 35. Italy Humira market, by distribution channel, 2018-2030 (USD Million)
Table 36. Spain Humira market, by product, 2018-2030 (USD Million)
Table 37. Spain Humira market, by application, 2018-2030 (USD Million)
Table 38. Spain Humira market, by distribution channel, 2018-2030 (USD Million)
Table 39. Norway Humira market, by product, 2018-2030 (USD Million)
Table 40. Norway Humira market, by application, 2018-2030 (USD Million)
Table 41. Norway Humira market, by distribution channel, 2018-2030 (USD Million)
Table 42. Denmark Humira market, by product, 2018-2030 (USD Million)
Table 43. Denmark Humira market, by application, 2018-2030 (USD Million)
Table 44. Denmark Humira market, by distribution channel, 2018-2030 (USD Million)
Table 45. Sweden Humira market, by product, 2018-2030 (USD Million)
Table 46. Sweden Humira market, by application, 2018-2030 (USD Million)
Table 47. Sweden Humira market, by distribution channel, 2018-2030 (USD Million)
Table 48. Asia Pacific Humira market, by country, 2018-2030 (USD Million)
Table 49. Asia Pacific Humira market, by product, 2018-2030 (USD Million)
Table 50. Asia Pacific Humira market, by application, 2018-2030 (USD Million)
Table 51. Asia Pacific Humira market, by distribution channel, 2018-2030 (USD Million)
Table 52. Japan Humira market, by product, 2018-2030 (USD Million)
Table 53. Japan Humira market, by application, 2018-2030 (USD Million)
Table 54. Japan Humira market, by distribution channel, 2018-2030 (USD Million)
Table 55. China Humira market, by product, 2018-2030 (USD Million)
Table 56. China Humira market, by application, 2018-2030 (USD Million)
Table 57. China Humira market, by distribution channel, 2018-2030 (USD Million)
Table 58. India Humira market, by product, 2018-2030 (USD Million)
Table 59. India Humira market, by application, 2018-2030 (USD Million)
Table 60. India Humira market, by distribution channel, 2018-2030 (USD Million)
Table 61. Australia Humira market, by product, 2018-2030 (USD Million)
Table 62. Australia Humira market, by application, 2018-2030 (USD Million)
Table 63. Australia Humira market, by distribution channel, 2018-2030 (USD Million)
Table 64. South Korea Humira market, by product, 2018-2030 (USD Million)
Table 65. South Korea Humira market, by application, 2018-2030 (USD Million)
Table 66. South Korea Humira market, by distribution channel, 2018-2030 (USD Million)
Table 67. Thailand Humira market, by product, 2018-2030 (USD Million)
Table 68. Thailand Humira market, by application, 2018-2030 (USD Million)
Table 69. Thailand Humira market, by distribution channel, 2018-2030 (USD Million)
Table 70. Latin America Humira market, by country, 2018-2030 (USD Million)
Table 71. Latin America Humira market, by product, 2018-2030 (USD Million)
Table 72. Latin America Humira market, by application, 2018-2030 (USD Million)
Table 73. Latin America Humira market, by distribution channel, 2018-2030 (USD Million)
Table 74. Brazil Humira market, by product, 2018-2030 (USD Million)
Table 75. Brazil Humira market, by application, 2018-2030 (USD Million)
Table 76. Brazil Humira market, by distribution channel, 2018-2030 (USD Million)
Table 77. Argentina Humira market, by product, 2018-2030 (USD Million)
Table 78. Argentina Humira market, by application, 2018-2030 (USD Million)
Table 79. Argentina Humira market, by distribution channel, 2018-2030 (USD Million)
Table 80. Middle East & Africa Humira market, by country, 2018-2030 (USD Million)
Table 81. Middle East & Africa Humira market, by product, 2018-2030 (USD Million)
Table 82. Middle East & Africa Humira market, by application, 2018-2030 (USD Million)
Table 83. Middle East & Africa Humira market, by distribution channel, 2018-2030 (USD Million)
Table 84. South Africa Humira market, by product, 2018-2030 (USD Million)
Table 85. South Africa Humira market, by application, 2018-2030 (USD Million)
Table 86. South Africa Humira market, by distribution channel, 2018-2030 (USD Million)
Table 87. Saudi Arabia Humira market, by product, 2018-2030 (USD Million)
Table 88. Saudi Arabia Humira market, by application, 2018-2030 (USD Million)
Table 89. Saudi Arabia Humira market, by distribution channel, 2018-2030 (USD Million)
Table 90. UAE Humira market, by product, 2018-2030 (USD Million)
Table 91. UAE Humira market, by application, 2018-2030 (USD Million)
Table 92. UAE Humira market, by distribution channel, 2018-2030 (USD Million)
Table 93. Kuwait Humira market, by product, 2018-2030 (USD Million)
Table 94. Kuwait Humira market, by application, 2018-2030 (USD Million)
Table 95. Kuwait Humira market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Humira market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and application outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Humira market dynamics
Figure 12 Humira market: Porter’s five forces analysis
Figure 13 Humira market: PESTLE analysis
Figure 14 Product market, 2018-2030 (USD Million)
Figure 15 Branded market, 2018-2030 (USD Million)
Figure 16 Biosimilar market, 2018-2030 (USD Million)
Figure 17 Application market, 2018-2030 (USD Million)
Figure 18 Rheumatoid Arthritis market, 2018-2030 (USD Million)
Figure 19 Psoriatic Arthritis market, 2018-2030 (USD Million)
Figure 20 Crohn’s Diseases market, 2018-2030 (USD Million)
Figure 21 Ulcerative Colitis market, 2018-2030 (USD Million)
Figure 22 Ankylosing Spondylitis market, 2018-2030 (USD Million)
Figure 23 Others market, 2018-2030 (USD Million)
Figure 24 Distribution Channel market, 2018-2030 (USD Million)
Figure 25 Hospital Pharmacies market, 2018-2030 (USD Million)
Figure 26 Retail Pharmacies market, 2018-2030 (USD Million)
Figure 27 Online Pharmacies market, 2018-2030 (USD Million)
Figure 28 Humira market revenue, by region
Figure 29 Regional marketplace: Key takeaways
Figure 30 Regional marketplace: Key takeaways
Figure 31 North America Humira market, 2018-2030 (USD Million)
Figure 32 U.S. country dynamics
Figure 33 U.S. Humira market, 2018-2030 (USD Million)
Figure 34 Canada country dynamics
Figure 35 Canada Humira market, 2018-2030 (USD Million)
Figure 36 Mexico country dynamics
Figure 37 Mexico Humira market, 2018-2030 (USD Million)
Figure 38 Europe Humira market, 2018-2030 (USD Million)
Figure 39 UK country dynamics
Figure 40 UK Humira market, 2018-2030 (USD Million)
Figure 41 Germany country dynamics
Figure 42 Germany Humira market, 2018-2030 (USD Million)
Figure 43 France country dynamics
Figure 44 France Humira market, 2018-2030 (USD Million)
Figure 45 Italy country dynamics
Figure 46 Italy Humira market, 2018-2030 (USD Million)
Figure 47 Spain country dynamics
Figure 48 Spain Humira market, 2018-2030 (USD Million)
Figure 49 Norway country dynamics
Figure 50 Norway Humira market, 2018-2030 (USD Million)
Figure 51 Sweden country dynamics
Figure 52 Sweden Humira market, 2018-2030 (USD Million)
Figure 53 Denmark country dynamics
Figure 54 Denmark Humira market, 2018-2030 (USD Million)
Figure 55 Asia Pacific Humira market, 2018-2030 (USD Million)
Figure 56 Japan country dynamics
Figure 57 Japan Humira market, 2018-2030 (USD Million)
Figure 58 China country dynamics
Figure 59 China Humira market, 2018-2030 (USD Million)
Figure 60 India country dynamics
Figure 61 India Humira market, 2018-2030 (USD Million)
Figure 62 Australia country dynamics
Figure 63 Australia Humira market, 2018-2030 (USD Million)
Figure 64 South Korea country dynamics
Figure 65 South Korea Humira market, 2018-2030 (USD Million)
Figure 66 Thailand country dynamics
Figure 67 Thailand Humira market, 2018-2030 (USD Million)
Figure 68 Latin America Humira market, 2018-2030 (USD Million)
Figure 69 Brazil country dynamics
Figure 70 Brazil Humira market, 2018-2030 (USD Million)
Figure 71 Argentina country dynamics
Figure 72 Argentina Humira market, 2018-2030 (USD Million)
Figure 73 MEA Humira market, 2018-2030 (USD Million)
Figure 74 South Africa country dynamics
Figure 75 South Africa Humira market, 2018-2030 (USD Million)
Figure 76 Saudi Arabia country dynamics
Figure 77 Saudi Arabia Humira market, 2018-2030 (USD Million)
Figure 78 UAE country dynamics
Figure 79 UAE Humira market, 2018-2030 (USD Million)
Figure 80 Kuwait country dynamics
Figure 81 Kuwait Humira market, 2018-2030 (USD Million)
Figure 82 Company categorization
Figure 83 Company market position analysis
Figure 84 Strategic framework

Companies Mentioned

The major companies featured in this Humira market report include:
  • Alvotech
  • Amgen Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • CELLTRION INC.
  • Coherus BioSciences, Inc.
  • Fresenius Kabi AG
  • FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
  • Pfizer Inc.
  • Samsung Bioepis
  • Sandoz Inc.

Related Topics

Related Reports

Humira Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Humira Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 91 Pages
  • Global
From
Humira Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Humira Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 184 Pages
  • Global
From
Humira Biosimilar Global Market Report 2025 - Product Image

Humira Biosimilar Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Humira Drug Market Report 2025 - Product Image

Humira Drug Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.